Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Gastroenterología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Reclutando
Fase 3
ClinicalTrials.gov
A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) and Fibrosis Stages F2 and F3
INTERVENTIONAL
Inicio: 19 de ago de 2021
ID: NCT04849728
Completado
Fase 2
ClinicalTrials.gov
A Phase II Randomized, Open-Label, Multicenter Study Comparing CO-1.01 With Gemcitabine as First-Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma
INTERVENTIONAL
Inicio: 1 de may de 2010
ID: NCT01124786
Completado
Fase 3
ClinicalTrials.gov
A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Moderately to Severely Active Ulcerative Colitis
INTERVENTIONAL
Inicio: 1 de nov de 2006
ID: NCT00408629
Completado
Fase 2
ClinicalTrials.gov
A 12-week Randomized, Patient and Investigator Blinded, Placebo-controlled, Parallel Group Study to Investigate the Efficacy of LIK066 in Obese Patients With Non-alcoholic Steatohepatitis (NASH)
INTERVENTIONAL
Inicio: 4 de oct de 2017
ID: NCT03205150
Terminado
Fase 4
ClinicalTrials.gov
AN OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE PHARMACOKINETICS OF SINGLE AND MULTIPLE INTRAVENOUS DOSES OF PANTOPRAZOLE IN TWO AGE COHORTS OF HOSPITALIZED PEDIATRIC SUBJECTS 1 TO 16 YEARS OF AGE WHO ARE CANDIDATES FOR ACID SUPPRESSION THERAPY
INTERVENTIONAL
Inicio: 9 de may de 2017
ID: NCT02401035
Reclutando
Fase 3
ClinicalTrials.gov
A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Induction Therapy With RO7790121 in Patients With Moderately to Severely Active Crohn's Disease
INTERVENTIONAL
Inicio: 12 de may de 2025
ID: NCT06819891
Completado
Fase 2
ClinicalTrials.gov
A Phase 2B Study of BMS-790052 in Combination With Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1 Infected Subjects Who Are Null or Partial Responders to Prior Treatment With Peginterferon Alfa Plus Ribavirin Therapy
INTERVENTIONAL
Inicio: 1 de ago de 2010
ID: NCT01170962
Aún no recluta
ClinicalTrials.gov
Association Between Fatty Liver and Pancreatic Steatosis in Patients With Metabolic Syndrome
OBSERVATIONAL
Inicio: 1 de sept de 2025
ID: NCT06757348
Reclutando
ClinicalTrials.gov
An Observational Study in Patients With Unresectable Hepatocellular Carcinoma (uHCC) Following Treatment With Atezolizumab Plus Bevacizumab (AB) or With Another Approved Immuno-oncology Immune Checkpoint Inhibitor Combination in First-line
OBSERVATIONAL
Inicio: 27 de nov de 2023
ID: NCT06117891
Reclutando
Fase 3
ClinicalTrials.gov
AFFIRM: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
INTERVENTIONAL
Inicio: 7 de sept de 2023
ID: NCT06051617
Completado
Fase 3
ClinicalTrials.gov
Phase3 Study to Evaluate the Efficacy and Safety of AlbuminInterferon in Combination With Ribavirin Compared With Peginterferon in Combination With Ribavirin in Interferon Alfa Naive Subjects With CHC Genotype 2/3.
INTERVENTIONAL
Inicio: 1 de feb de 2007
ID: NCT00411385
Completado
Fase 3
ClinicalTrials.gov
A Multi-centre Long Term Follow-up Study to Assess the Durability of Sustained Virologic Response in Alisporivir-treated Chronic Hepatitis C Patients
INTERVENTIONAL
Inicio: 1 de dic de 2011
ID: NCT02753699
Completado
Fase 3
ClinicalTrials.gov
A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 µg [2 Actuations of 2.5 ug] and 10 ug [2 Actuations of 5 ug]) Delivered by the Respimat® Inhaler, and 48 Weeks of Twice Daily Foradil® (12 µg) Delivered by the Aerolizer® Inhaler, in Patients With Chronic Obstructive Pulmonary Disease (COPD)
INTERVENTIONAL
Inicio: 1 de ene de 2009
ID: NCT00796653
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 as Induction and Maintenance Therapy for Moderate to Severe Ulcerative Colitis
INTERVENTIONAL
Inicio: 17 de jun de 2015
ID: NCT02435992
Completado
Fase 2
ClinicalTrials.gov
A Randomized, Open-label, Dose-escalation to Rash Study to Assess the Effect of Tarceva in Combination With Gemcitabine on Overall Survival in Patients With Metastatic Pancreatic Cancer.
INTERVENTIONAL
Inicio: 1 de may de 2008
ID: NCT00652366
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of VAY736 in Autoimmune Hepatitis
INTERVENTIONAL
Inicio: 15 de feb de 2018
ID: NCT03217422
Completado
Fase 2
ClinicalTrials.gov
Phase IIb Multi-Center, Randomised, Partial-Blind Parallel Cohort Study to Assess the Efficacy and Safety of Treatment With GSK3228836 in Participants With Chronic Hepatitis B Virus (B-Clear)
INTERVENTIONAL
Inicio: 27 de jul de 2020
ID: NCT04449029
Completado
Fase 2
ClinicalTrials.gov
An Open Label, Stratified, Single-arm Phase II Study of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumor (NET) After Failure of Cytotoxic Chemotherapy
INTERVENTIONAL
Inicio: 1 de jun de 2006
ID: NCT00363051
Completado
Fase 3
ClinicalTrials.gov
A Multicenter, Three Arm, Randomized, Open Label Clinical Study to Compare Renal Function in Liver Transplant Recipients Receiving an Immunosuppressive Regimen of Advagraf (Immediately or Delayed Post-transplant) and MMF With or Without a Monoclonal Anti-IL2R Antibody (Basiliximab)
INTERVENTIONAL
Inicio: 30 de sept de 2009
ID: NCT01011205
Completado
Fase 3
ClinicalTrials.gov
A Randomised, Double-blind, Parallel Group Study to Assess the Efficacy and Safety of 52 Weeks of Once Daily Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (2.5 µg / 5 µg; 5 µg / 5 µg) (Delivered by the Respimat® Inhaler) Compared With the Individual Components (2.5 µg and 5 µg Tiotropium, 5 µg Olodaterol) (Delivered by the Respimat® Inhaler) in Patients With Chronic Obstructive Pulmonary Disease (COPD). [TOnado TM 1]
INTERVENTIONAL
Inicio: 1 de sept de 2011
ID: NCT01431274
Anterior
1
...
23
24
25
...
434
Siguiente
Filtros